Cancerguard® Multi-Cancer Early Detection Test
Use
Cancerguard is a blood-based multi-cancer early detection (MCED) test designed to identify cancer-associated signals across multiple tumor types. It is intended for use in asymptomatic adults to support earlier detection of cancers, including those without established screening protocols. The test analyzes alterations in circulating tumor DNA and tumor-associated protein levels and is not intended for diagnosis, therapy selection, or disease monitoring.
Special Instructions
The test is indicated for adults aged 50–84 with no known cancer diagnosis within the past three years and should be used in conjunction with guideline-recommended cancer screenings. Blood samples must be collected and handled according to specified protocols to preserve cfDNA and protein integrity. Patients should be counseled on the potential need for follow-up diagnostic evaluation, which may include imaging procedures.
Limitations
Cancerguard does not detect all cancer types and was not evaluated for certain cancers, including breast and prostate cancer, or for pre-cancerous lesions. False positive and false negative results may occur, and a negative result does not exclude the presence of cancer. A positive result requires further clinical evaluation to confirm the presence, type, and location of malignancy.
Methodology
Composite
Biomarkers
Result Turnaround Time
10-14 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
Peripheral blood draw required using appropriate collection and handling protocols to preserve cfDNA and protein integrity.
Other tests from different labs that may be relevant